KR101654308B1 - Composition for improving hair having effect of depilation prevention and good hair - Google Patents
Composition for improving hair having effect of depilation prevention and good hair Download PDFInfo
- Publication number
- KR101654308B1 KR101654308B1 KR1020090062850A KR20090062850A KR101654308B1 KR 101654308 B1 KR101654308 B1 KR 101654308B1 KR 1020090062850 A KR1020090062850 A KR 1020090062850A KR 20090062850 A KR20090062850 A KR 20090062850A KR 101654308 B1 KR101654308 B1 KR 101654308B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- extract
- composition
- ginseng
- contained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000000694 effects Effects 0.000 title claims abstract description 37
- 230000003752 improving hair Effects 0.000 title description 5
- 230000002265 prevention Effects 0.000 title description 2
- 230000035617 depilation Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 40
- 235000008434 ginseng Nutrition 0.000 claims abstract description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 210000002268 wool Anatomy 0.000 claims abstract description 18
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 9
- 241000411851 herbal medicine Species 0.000 claims abstract description 7
- 241000208340 Araliaceae Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 229940009456 adriamycin Drugs 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 abstract description 16
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 9
- 229940107131 ginseng root Drugs 0.000 abstract description 6
- 230000003779 hair growth Effects 0.000 abstract description 6
- 210000003135 vibrissae Anatomy 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 240000004371 Panax ginseng Species 0.000 description 22
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 201000004384 Alopecia Diseases 0.000 description 13
- 208000024963 hair loss Diseases 0.000 description 12
- 230000003676 hair loss Effects 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 210000004761 scalp Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 239000012676 herbal extract Substances 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003048 aphrodisiac agent Substances 0.000 description 2
- 230000002509 aphrodisiac effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 239000008266 hair spray Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940117382 propecia Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000003793 Rhizophora mangle Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- DKDJRHFSBKAGSF-UHFFFAOYSA-N benzyl(nonadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCC[NH2+]CC1=CC=CC=C1 DKDJRHFSBKAGSF-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037376 facial hyperhidrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003051 hair bleaching agent Substances 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 230000003781 hair follicle cycle Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은, 조직배양한 산삼 부정근 추출물 및 동의보감에 수록된 금주녹운유 처방에 포함된 한약재 천연 복합 추출물을 함유하는 탈모 예방 및 양모 효과를 갖는 모발 개선용 조성물을 제공한다.The present invention provides a composition for preventing hair loss and having a hair-wool effect, which comprises a natural combination extract of a herbal medicine contained in a prescription of a ginseng root oil contained in a cultured ginseng adventitious root extract and a ginseng root extract.
이에, 조직배양한 산삼 부정근 추출물 및 한약재 천연 복합 추출물의 혼합물이, 5α-환원효소 활성을 억제하여 래트 진모 모낭(Rat vibrissa hair follicle)의 분리 배양을 이용한 육모 성장 실험에서 뛰어난 효과를 나타내므로 탈모 예방, 개선 및 양모 효과를 제공할 수 있다.Thus, the mixture of the cultured ginseng adventitious roots extract and the natural combination of herbal medicines suppressed 5α-reductase activity and exhibited excellent effects in the hair growth test using the isolated cultivation of rat rhizomal follicle (Rat vibrissa hair follicle) , Improvement and wool effect.
모발개선, 생약 복합 추출물, 산삼 부정근 추출물 Hair enhancement, herbal medicine complex extract, wild ginseng root extract
Description
본 발명은, 모발 개선용 조성물에 관한 것으로서, 구체적으로는 조직배양한 산삼 부정근 추출물과 동의보감의 금주녹운유 처방의 생약 복합 추출물을 유효성분으로 함유하는 탈모 예방 및 양모 효과를 갖는 모발 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving hair, and more particularly, to a hair improving composition having hair loss prevention effect and hair wool effect containing as an active ingredient a ginseng adriamycin root extract obtained by tissue culture and a herbal medicine combination extract of Dong- .
일반적으로 탈모의 원인은 남성호르몬에 의한 작용, 혈액순환의 불량으로 인한 혈류량 감소로 인한 모근부의 신진대사 기능저하, 영양부족, 약물에 의한 부작용, 비듬균이나 세균에 의한 두피 손상, 유전적 요인 등이 알려져 있다. 또한, 과도한 샴푸, 건조, 헤어스타일링 등으로 인한 두피 및 모발의 자극과 화학 세정성분에 의한 두피의 천연 보습성분이 제거됨으로써 두피 및 모발이 손상을 받는 것으로 알려져 있다. 특히, 최근에는 사회 환경 등의 변화로 인한 스트레스의 과도한 증가로 탈모 및 모발 손상 증상으로 고민하는 인구가 늘어나는 추세이고, 연령대 및 성별의 제한 및 경계 또한 넓어지고 있는 상황이다.In general, hair loss is caused by male hormone, deterioration of metabolic function due to decrease of blood flow due to poor blood circulation, malnutrition, side effects due to drugs, scalp damage caused by dandruce or bacteria, genetic factors It is known. It is also known that scalp and hair are damaged due to excessive stimulation of scalp and hair due to excessive shampoo, drying, hair styling, and removal of natural moisturizing ingredients of the scalp due to chemical cleaning ingredients. Especially, in recent years, due to excessive increase of stress due to changes in the social environment, the number of people suffering from hair loss and hair damage symptoms is increasing, and age and gender limitations and boundaries are also widening.
평균적으로 사람의 모발의 개수는 약 10만에서 12만 개이다. 모발은 발생, 성장, 퇴행, 휴지기라는 라이프 사이클이 있으며 휴지기에 돌입한 머리카락이 보통 하루에 50~100개 정도 빠지는 것이 정상이다. 모발은 일정기간 자라면 빠지고 새로운 모발이 난다. 손톱이나 발톱과는 달리 '자라고-쉬고-빠지고'하는 주기를 가지는 것이다. 털갈이를 하는 동물의 경우 전체 털의 모주기(毛週期)가 동일하기 때문에 털이 동시에 빠지고 새로 나는 이른바 털갈이를 하게 된다. 그러나 인간의 모발은 각각 독자적인 모주기를 갖고 있기 때문에 털갈이 없이 항상 일정한 모발 수를 유지하게 된다. 인간 모발의 경우는 3년 자란 후 빠지고 다시 그 자리에서 3개월 후 새로 모발이 난다. 모발은 약 10~12만 개가 있으며 이 중 하루에 70여 개가 빠지며 3개월 전에 빠진 70여 개의 모발은 새로 자라나게 되어 모발은 항상 10~12만 개를 유지한다.On average, the number of human hair is about 100,000 to 120,000. Hair has a life cycle of development, growth, degeneration, and dormancy, and it is normal that the hair that enters the dormant period usually falls in the range of 50 ~ 100 per day. If the hair grows for a certain period of time, it will fall out and bring new hair. Unlike fingernails or claws, it has a cycle of "growing, resting, and falling". In the case of the molting animals, the hairs are falling at the same time because of the same hair follicle cycle (hair follicle period), so that the new hull is molted. However, since each human hair has its own mother cycle, it always maintains a constant number of hair without molting. In the case of human hair, it grows after 3 years, and after 3 months from that position, new hair is born. There are about 100,000 to 120,000 hairs, of which 70 are lost a day. More than 70 hairs that were lost three months ago are newly developed, and hair is always kept at 10 to 120 thousand.
각각의 모발은 서로 다른 주기를 갖고 성장기(anagen), 퇴행기(catagen), 및 휴지기(telogen)를 거쳐 성장, 탈락한다. 이러한 주기는 3 내지 6년에 걸쳐서 반복되는데, 이 결과 하루 평균 50 내지 100개의 모발이 정상적으로 탈락하게 된다.Each hair grows and falls through anagen, catagen, and telogen with different cycles. This cycle is repeated over 3 to 6 years, resulting in an average of 50 to 100 hairs dropping normally on a daily basis.
모발은 두피에 뿌리를 두고 혈액으로부터 영양분을 공급받는데, 장기간에 걸쳐 모세혈관이 축소되고 두피가 얇아져 모발이 정상적으로 발육할 수 없는 상태에 이르면 그 부위의 머리카락은 점점 가늘어지면서 특정 부위의 머리카락 수명이 짧아지게 되고, 수명이 짧아진 머리카락은 쉽게 빠지게 될 뿐만 아니라, 상기와 같이 머리카락이 빠진 모공에서는 머리카락이 다시 나지 못하게 되어 결국은 빈모 증세가 나타난다. 또한, 모발의 성장과 발육에 필요한 에너지의 생성을 방해한다고 알려진 테스토스테론은 모낭 주변에 분포하고 있는 5α-환원효소의 작용으로 그 활성도가 보다 증가한 DHT (Dihydrotesosterone)로 변하고, 활성된 DHT는 안드로겐 수 용체와 결합함으로써 모발의 성장기를 단축하고, 모낭의 크기를 위축시킴으로써 모발을 점차 가늘게 만들며 결국에는 탈모를 유발한다.Hair is roots in the scalp and nutrients are supplied from the blood. When the capillaries are shrunk over a long period of time and the scalp becomes thin and the hair can not grow normally, the hair of the area becomes thinner and the hair life of the specific area is short The shortened life span of the hair is not only easily lost, but also in the pores in which the hair is missing, the hair does not come out again, resulting in the appearance of a papilloma. In addition, testosterone, known to interfere with the production of energy required for hair growth and development, is transformed into DHT (Dihydrotesosterone), the activity of which is increased by the action of 5α-reductase, which is distributed around the hair follicles. To shorten the growth period of the hair and shrink the size of the hair follicle to make the hair thinner and eventually to cause hair loss.
상기와 같은 탈모 현상으로 인한 빈모 증세를 방지하면서 두피의 모공에서 활발한 양모가 이루어질 수 있도록 하기 위한 목적으로 다양한 탈모 방지제 및 양모 촉진제가 개발되고 있다.Various anti-hair-reducing agents and wool-promoting agents have been developed for the purpose of enabling active wool to be formed in the pores of the scalp while preventing the symptoms of the bad hair caused by the hair loss phenomenon as described above.
이러한 탈모증의 치료 및 예방을 위해 널리 사용되고 있는 제제로는 미녹시딜(Minoxidil) 함유 제제를 들 수 있다. 미녹시딜은 전립선 치료제로 개발되었으나, 사용상 부작용으로 양모현상이 나타나면서 현재에는 양모제로 더 유명해진 약물이다. 그러나 미녹시딜 제제는 과다 사용 시 두피 건조, 홍반 등의 두피 자극 증상, 알레르기성 접촉 피부염, 안면부 다모증과 혈관 확장, 즉 항고혈압 작용에 의한 허탈감, 저혈압, 빈맥 등의 부작용을 일으켜 장기 사용에는 부적합한 것으로 밝혀졌다. 머크(Merck)사에서 개발한 프로페시아(propecia)는 남성호르몬 신진대사 효소인 5α-환원효소 억제제로 남성호르몬인 테스토스테론이 다이하이드로테스토스테론으로 전환되는 것을 억제함으로써 탈모를 방지한다. 그러나 이러한 효과는 사용시에는 그 약효가 유효하지만, 약의 사용을 중지하면 수개월 후 비복용자와 같이 탈모가 다시 진행되는 문제점이 있었고, 가격이 높고 복용 시 성욕감퇴, 발기부전 등의 부작용이 발생하는 것으로 보고되었다.Minoxidil-containing preparations are widely used as agents for the treatment and prevention of such alopecia. Minoxidil has been developed as a treatment for prostatitis, but nowadays it is becoming more famous as a hair-dressing agent because of wool symptoms due to side effects. However, minoxidil preparations were found to be unsuitable for long-term use due to side effects such as scalp irritation such as scalp drying, erythema, allergic contact dermatitis, facial hyperhidrosis and vasodilatation, hypotension caused by antihypertensive action, hypotension, lost. Propecia, developed by Merck, is a 5α-reductase inhibitor, a male hormone metabolizing enzyme, that prevents the conversion of testosterone, a testosterone, into dihydrotestosterone, thereby preventing hair loss. However, such effects are effective at the time of use, but when the use of the drug is stopped, hair loss is resumed as in the case of non-users after a few months, and high costs and side effects such as loss of sexual desire and erectile dysfunction occur .
이와 같이 지금까지 사용되고 있는 미녹시딜과 프로페시아는 양모와 탈모방지에는 특징적인 효과를 보여주고 있지만, 반면에 여러 가지 부작용으로 인하여 이를 장기적으로 사용하기에는 부적합한 것으로 보고되고 있다. 따라서 대부분의 탈 모환자들은 탈모증상을 완치하지는 못하지만 여러 가지 양모 촉진제들을 번갈아 사용해 가면서 일시적인 개선효과에 만족해하는 실정이다.Thus, minoxidil and propecia, which have been used so far, exhibit distinctive effects in preventing wool and hair loss, but are reported to be unsuitable for long-term use due to various side effects. Therefore, although most hair removal patients do not cure hair loss symptoms, they are satisfied with the temporary improvement effect by using various wool promoting agents alternately.
본 발명자들은 한방원료로부터 보다 안전하고 장기적인 사용이 가능한 양모 효과를 가지는 원료 개발을 위해 조직배양한 산삼 부정근 추출물(이하 ‘산삼 부정근 추출물’이라고 함)과 동의보감에 수록된 양모 관련 처방 원료로부터 양모 효과를 탐색한 결과 금주녹운유 처방의 한약재 복합 추출물(이하 ‘금주녹운유 추출물’이라고 함)로부터 양모 효과가 우수하게 나타남을 확인하였다.The present inventors have searched for the effect of wool from wool-related prescription raw materials listed in Sansam Root Extract (hereinafter referred to as "Sansam Root Extract") and Dongwoo Boo-gop (Rice ginseng root extract) for the development of raw materials having a wool effect that can be safer and longer- As a result, it was confirmed that the wool effect was excellent from the herbal medicine composite extract (hereinafter referred to as "Jinju ranun oil extract"
이에, 본 발명의 목적은, 양모와 탈모방지의 효과를 나타내면서 성욕감퇴, 발기부전, 허탈감, 저혈압, 빈맥 등의 부작용이 거의 없는 한방추출물 금주녹운유와 조직배양한 산삼 부정근 추출물의 혼합물을 이용하여 새로운 양모와 탈모방지 조성물을 제공하는 것이다.It is therefore an object of the present invention to provide a method for the treatment of hair loss and hair loss by using a mixture of a herbal extract, an antioxidant extract and a cultured ginseng extract, which shows little or no adverse effects such as loss of sexual desire, erectile dysfunction, hypothalamus, hypotension, To provide new wool and hair loss prevention compositions.
본 발명은, 조직배양한 산삼 부정근 추출물 및 동의보감에 수록된 금주녹운유 처방에 포함된 한약재 천연 복합 추출물을 함유하는 탈모 예방 및 양모 효과를 갖는 모발 개선용 조성물을 제공한다.The present invention provides a composition for preventing hair loss and having a hair-wool effect, which comprises a natural combination extract of a herbal medicine contained in a prescription of a ginseng root oil contained in a cultured ginseng adventitious root extract and a ginseng root extract.
본 발명에 따른 모발 개선용 조성물을 포함하는 화장료 조성물을 제공한다.There is provided a cosmetic composition comprising the hair improving composition according to the present invention.
본 발명에 따르면, 5α-환원효소 활성을 억제하여 래트 진모 모낭(Rat vibrissa hair follicle)의 분리 배양을 이용한 육모 성장 실험에서 뛰어난 효과를 나타내므로 탈모 예방, 개선 및 양모 효과를 제공할 수 있다.According to the present invention, since the 5α-reductase activity is inhibited and the hair growth test using the isolated cultivation of the rat rhizome hair follicle (Rat vibrissa hair follicle) shows an excellent effect, it is possible to provide hair loss prevention, improvement and wool effect.
본 발명에 따른 탈모 예방 및 양모 효과를 갖는 모발 개선용 조성물은, 조직배양한 산삼 부정근 추출물 및 동의보감에 수록된 금주녹운유 처방에 포함된 한약재 천연 복합 추출물을 함유하는 것을 특징으로 한다.The composition for preventing hair loss and hair for improving hair loss according to the present invention is characterized by containing a ginseng adriamycin root extract obtained by tissue culture and a natural combination extract of Chinese medicine contained in a prescription of Jinju ranchu oil contained in Dongbokgam.
여기서, 금주녹운유는 동의보감 외형편에 수록되어 있는 한방 처방으로 머리털을 나게 하는 효능이 있는 것으로 기록되어 있으며, 첨가된 한약재로는 만형자, 구릿대, 침향, 한련초, 방풍, 복분자, 생지황, 영릉향, 망초, 정향, 권백, 척촉화, 및 가자피로 구성되어 있다.Here, it is noted that Jinju ranun oil is an oriental medicine prescribed in the Dongbu Bohak section of the Dongbu bohak section, and it is said that it has an efficacy to excrete hair. The added medicinal materials include Manjang, Guri, Deokhyang, , Mangrove, clove, gangbyeong, texture, and lettuce.
이처럼 상기 한약재 천연 복합 추출물은, 만형자, 구릿대, 침향, 한련초, 방풍, 복분자, 생지황, 영릉향, 망초, 정향, 권백, 척촉화 및 가자피의 추출물일 수 있다.Thus, the natural herbal extract of the medicinal herb composition may be an extract of Ganoderma lucidum, Guerbet, Eucalyptus, Hansikcho, Windblown, Rubus spp.
금주녹운유와 함께 예로부터 신비한 영약으로 취급되는 희귀식물로서 여러 다양한 질병치료제 및 보양제로 이용되어 온 산삼을 인공적으로 조직배양 하여 추출한 추출물을 함께 사용하였다. This is a rare plant which is treated as a mysterious herb medicine together with a weekly rust oiled milk. An extract of artificially cultured wild ginseng which has been used as a therapeutic agent for various diseases and an aphrodisiac is used together.
산삼은 기능성 성분을 다량 함유한 식물의 하나의 예로, 오갈과(Araliacea), 인삼(Panax ginseng C.A. Meyer)에 속하는 산에서 자연적으로 자라는 인삼으로, 새싹이 나올 때, 꽃을 맺는 꽃대가 잎 및 줄기와 함께 나오는 현화식물에 속하면서 피자식물에도 속하며, 반음지성식물이다. 동의보감에서는 '신초'라 기록된 바 있으며, 예로부터 신비한 영약으로 취급되는 희귀식물로서 여러 다양한 질병치료제 및 보양제로 이용되어왔다.Ginseng is an example of a plant that contains a large amount of functional ingredients. It is a ginseng that grows naturally in the mountains belonging to Araliacea and Panax ginseng CA Meyer. When the bud comes out, the flower- It belongs to a flowering plant together with a pizza plant, and it is a semicellular plant. It has been recorded as 'Shinsho' in Dongbokgop, and it has been used as a variety of disease remedy and aphrodisiac since it is a rare plant treated as a mysterious dragon.
임상학적 연구결과로 보고된 인삼의 효능으로는, 항당뇨 작용, 항암 작용, 심장 강화 및 혈압 조정, 간기능 강화, 위장기능강화, 스트레스 해소 및 강장 효과, 체력(정력) 증진, 뇌기능 강화, 노화 억제, 방사선 조사 방어작용, 빈혈 회복 효과 및 조혈 작용, 면역 기능 증진, 소염 작용 및 허약체질 개선 효과 등이 있다. 산삼의 효능은 인삼과 비슷하나 약리적 효과면에서 훨씬 뛰어나다고 알려져 있다.The ginseng efficacy reported in clinical studies includes antidiabetic action, anticancer action, cardiac strengthening and blood pressure control, liver function enhancement, gastrointestinal function enhancement, stress relief and tonic effect, physical strength (tack) Anti-aging, radiation protection, anemia recovery and hematopoiesis, immunity, anti-inflammation and fragility. The efficacy of ginseng is similar to that of ginseng, but it is known to be superior in terms of pharmacological effects.
산삼은 천종, 지종, 인종, 장뇌 이상의 4가지로 분류되는데, 상세하게는 자연적으로 산에서 나서 씨가 떨어져 생긴 천종(천연산삼), 야생동물이나 조류가 산삼 씨를 먹고 산중에 배설하여 자란 지종, 사람이 씨를 뿌려 자란 인종, 및 산삼의 종자를 채취하여 깊은 산속에 씨를 뿌려 야생상태로 인위적으로 양생시킨 장뇌(가삼)이다. 일반적으로는 야생산삼은 종자를 뿌려도 싹이 잘 나오지 않고, 설사 자란다고 해도 몇 년을 넘기지 못하고 썩어 없어지는 경우가 많아 재배가 쉽지 않은 아주 귀한 식물이다.The wild ginseng is classified into four kinds such as ten kinds, geographical species, race, camphor, and more specifically, it is classified into four kinds of ginseng (natural ginseng) It is the rabbit raised by sowing this seed and the camphor (ginseng) which picked up the seed of the wild ginseng and artificially cured it in the wild state by sowing in the deep mountain. In general, wild ginseng is a very precious plant that is not easy to cultivate because it does not come out well even if seeds are sprinkled, and even if it grows, it does not pass for many years and rots away.
본 발명에 따른 모발 개선용 조성물 100중량%에 대해, 상기 한약재 천연 복합 추출물 10~90중량% 및 상기 조직배양한 산삼 부정근 추출물 10~90중량%로 포함될 수 있다.10 to 90% by weight of the natural herbal extract of the herbal composition and 10 to 90% by weight of the ginseng adventitious root extract of the present invention may be contained in 100% by weight of the hair improving composition according to the present invention.
여기서, 상기 한약재 천연 복합 추출물 및 상기 조직배양한 산삼 부정근 추출물은, 정제수를 포함한 물; 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매; 헥산; 부틸렌글리콜; 프로필렌글리콜; 글리세린; 초산에칠; 에테르; 및 클로로포름으로 구성된 그룹으로부터 선택된 1종 이상의 용매로 추출한 성분일 수 있다.Herein, the natural herbal composition extract and the cultured ginseng adriamycin root extract include water containing purified water; A lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof; Hexane; Butylene glycol; Propylene glycol; glycerin; Acetic acid; ether; And chloroform. ≪ / RTI >
한편, 본 발명에 따른 모발 개선용 조성물은, 헤어토닉, 헤어컨디셔너, 헤어 에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어 에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 또는 헤어스프레이의 제형인 화장료 조성물일 수 있다.Meanwhile, the composition for improving hair according to the present invention can be used as a hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, Hair cream, hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair drying agent, hair preservative, hair dye, hair wave agent, hair bleaching agent, hair gel, hair glaze, hair dresser , A hair lacquer, a hair moisturizer, a hair mousse or a hair spray.
이 경우, 화장료 조성물 총 중량에 대해, 상기 모발 개선용 조성물이 0.1~50중량%로 포함될 수 있다.In this case, the hair improving composition may be contained in an amount of 0.1 to 50% by weight based on the total weight of the cosmetic composition.
이와 같이, 본 발명에 따르면, 양모와 탈모방지의 효과를 나타내면서 성욕감퇴, 발기부전, 허탈감, 저혈압, 빈맥 등의 부작용이 거의 없는 한방추출물 금주녹운유와 조직배양한 산삼 부정근 추출물의 혼합물을 이용하여 새로운 양모와 탈모방지 조성물을 제공할 수 있다.As described above, according to the present invention, by using a mixture of a herbal extract, a Jinju ranun oil and a tissue-cultured ginseng extract, which exhibits the effect of preventing wool and hair loss and has no side effects such as loss of sex, erectile dysfunction, hypothalamus, hypotension and tachycardia New wool and hair loss preventing compositions can be provided.
이하에서는, 본 발명을 실시예 및 실험예로 상세히 설명하기로 한다. 그러나, 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples. However, the examples and experimental examples are illustrative of the present invention, and the content of the present invention is not limited to the following examples and experimental examples.
제조예 1(금주녹운유 추출물의 제조)Production Example 1 (Preparation of a green tea oil extract of this week)
경동시장에서 구입한 금주녹운유 처방의 한약재를 건조하고 세절하여 70% 에탄올 수용액 3 L에 1 kg이 되게 동량으로 첨가한 후 3일 동안 교반 추출한 다음 여과하였다(Whatman No.5, whatman international Ltd, 영국). 이 여과액을 회전감압농축하여 금주녹운유 추출 분말 114g을 수득하였다.The herb medicines purchased from Kyungdong market were dried and cut into 3 L of 70% aqueous ethanol solution in an amount equal to 1 kg, followed by stirring for 3 days, followed by filtration (Whatman No.5, whatman international Ltd, England). The filtrate was concentrated under reduced pressure to obtain 114 g of a caustic rancid oil-extracted powder.
제조예 2(산삼 부정근 추출물의 제조)Production Example 2 (Production of wild ginseng adventitia root extract)
발명에 쓰인 산삼 부정근은 한국등록특허 제353636호에 기재된 방법으로 조직배양하고, 대량증식한 것으로, 건조시킨 조직배양된 산삼 부정근 1㎏에 70% 에탄올 30㎏ 및 1,3-부틸렌글리콜 3㎏ 또는 프로필렌글리콜 3㎏을 혼합하였다. 그 다음 충분히 숙성시킨 후 여과지로 여과시켜 추출물을 얻고 다시 50~60℃에서 에탄올을 제거한 추출물을 얻었다.The wild ginseng adventitious root used in the invention was obtained by tissue culture and mass propagation as described in Korean Patent No. 353636. To 1 kg of dried ginseng adventitious roots, 30 kg of 70% ethanol and 3 kg of 1,3-butylene glycol Or 3 kg of propylene glycol were mixed. Then, it was aged sufficiently and then filtered with a filter paper to obtain an extract, which was further extracted with ethanol at 50 to 60 ° C.
실시예(탈모 예방 및 양모 효과를 갖는 모발 개선용 조성물의 제조)EXAMPLES (Preparation of compositions for preventing hair loss and improving hair with wool effect)
제조예 1의 금주녹운유 추출물 30중량% 및 제조예 2의 산삼 부정근 추출물70중량%를 혼합하여 모발 개선용 조성물을 제조하였다.A hair improving composition was prepared by mixing 30% by weight of the green tea oil extract of Preparation Example 1 and 70% by weight of the extract of the wild ginseng adventitia root of Preparation Example 2.
실험예 1(래트 진모 모낭(Rat vibrissa hair follicle)의 분리 배양을 이용한 육모 효과 실험)EXPERIMENTAL EXAMPLE 1 (Hair growth effect test using separate culturing of Rat vibrissa hair follicle)
실시예에서 얻은 모발 개선용 조성물의 양모 효과를 알아보기 위하여 장기배양법(Organ culture method)을 이용하여 하기와 같이 실험을 수행하였다(Jindo and Tsuboi, Jpn. J. Dermatol., 107, pp769-779, 1997; Imai et al., Arch. Dermatol. Res., 284, pp466-471, 1993; Jindo et. al., J. Dermatol. 20, pp756-762, 1993; Philpott et al., J. Cell Sci., 97, pp463-471, 1990).In order to examine the effect of the wool of the hair improving composition obtained in the examples, the following experiment was carried out using the organ culture method (Jindo and Tsuboi, Jpn. J. Dermatol., 107, pp769-779, J. Dermatol. 20, pp. 756-762, 1993; Philpott et al., J. Cell Sci. ≪ RTI ID = 0.0 > et al., & , 97, pp 463-471, 1990).
생후 3주령 래트로부터 분리한 진모 모낭(Vibrissa follcile)을 37℃, 5% CO2 항온기에 2시간 동안 배양하였다. 24 웰 플레이트의 각 웰당 500㎕의 William E medium을 넣고 각 웰 당 한 개의 모낭을 넣어서 37℃, 5% CO2 항온기에서 배양하였 다. 배양 중에 배지는 3 일마다 교환하고, 수용액 상태의 상기 추출물을 0.5, 1, 2.5, 5%의 농도로 처리하였으며 추출물이 모낭의 성장 효과에 미치는 영향을 알아보았다. 시간에 따른 모낭의 성장 효과를 관찰하기 위해 0일 및 14 일에 이미지분석기(Image analyzer, DP701 controller, Olympus)를 이용하여 배양한 모낭 길이를 측정하여 대조군 (vehicle)과 상대적인 모낭 성장률(%)을 하기 표 1에 나타내었다.Vibrissa follciles isolated from 3-week-old rats were incubated in a 5% CO 2 incubator at 37 ° C for 2 hours. 500 μl of William E medium was added to each well of a 24-well plate, and one hair follicle was added to each well, followed by incubation in a 5% CO 2 incubator at 37 ° C. During the cultivation, the medium was changed every 3 days, and the aqueous extract solution was treated at 0.5, 1, 2.5, and 5% concentrations. The effect of the extract on the growth of the hair follicles was examined. To observe the growth of hair follicles over time, the length of hair follicles cultured with an image analyzer (Image Analyzer, DP701 controller, Olympus) was measured at day 0 and 14, and the relative follicular growth rate (%) The results are shown in Table 1 below.
[표 1] [Table 1]
실험 결과, 상기 표 1에서 실시예의 조성물에 의해 시간이 지남에 따라 최고 약 43% 성장이 촉진되었고 추출물의 농도의존적으로 성장률을 보였다. 따라서, 본 발명의 한방 원료 조성물에 의한 모낭의 양모 효과가 뛰어남을 확인할 수 있었다.As a result, the maximum growth of about 43% was promoted over time, and the growth rate of the extract was dependent on the concentration. Therefore, it was confirmed that the hair follicle effect of the hair follicle by the herbal composition of the present invention is excellent.
실험예 2(5α-환원효소(reductase) 활성 실험)Experimental Example 2 (5? -Reductase activity test)
실시예의 조성물이 모낭의 육모 효과가 5α-환원효소 (5α-reductase) 활성 억제에 의한 것인지 알아보기 위하여 래트 전립선 (Rat prostate) 5α-환원효소를 이용하여 첨가한 [3H]테스토스테론([3H]Testosterone, T)이 [3H]디히드로테스토스테론 ([3H]Dihydrotestosterone, DHT)로 전환되는 양을 문헌에 기재된 방법을 이용하여 측정하였다 (Franck et al., Bioorganic & Medicinal Chemistry, 8, pp1479-1487, 2000).[ 3 H] testosterone ([ 3 H]) added with the rat prostate 5α-reductase was used to determine whether the composition of the example was due to inhibition of 5α-reductase activity in hair follicle hair follicles ] testosterone, T) is [3 H] dihydro-testosterone ([3 H] Dihydrotestosterone, the amount that is converted to DHT) were determined using the methods described in the literature (Franck et al., Bioorganic & Medicinal Chemistry, 8, pp1479 -1487,2000).
생후 7~8 주령인 윈스타 래트 (Wistar rat) 수컷으로부터 전립선을 분리하여 액체질소로 급랭하였다. 분리한 전립선의 무게를 측정하여 0.32 mM sucrose (Amresco Inc, USA)와 1 mM dithiothreitol (DTT, Sigma, USA)가 포함된 pH 6.5의 20 mM photassium phosphate buffer saline (PBS)를 1 g 당 5 ml 씩 첨가하였다. 전립선을 분쇄한 후, 1,000rpm으로 10분 원심분리하여 여과하고 그 상층액을 회수하여 초원심분리기(Ultra centrifuge, Beckman, USA)로 100,000 g로 90분 원심분리하여 실험에 사용하였다.Prostate was separated from male Wistar rat 7 ~ 8 weeks of age and quenched with liquid nitrogen. The prostate was weighed and weighed 5 ml per gram of 20 mM photometric phosphate buffer saline (PBS) containing 0.32 mM sucrose (Amresco Inc, USA) and 1 mM dithiothreitol (DTT, Sigma, USA) . The prostate was pulverized, centrifuged at 1,000 rpm for 10 minutes, filtered, and the supernatant was collected and centrifuged at 100,000 g for 90 minutes using an ultracentrifuge (Beckman, USA).
1.5 ml 마이크로 튜브에 250 μg의 5α-환원효소, 120 nCi [1,2,6,7-3H]-T, 200 μM NADPH (Calbiochem, US) 및 실시예의 조성물을 첨가하고 40 mM PBS (pH 6.6)로 500 ㎕로 맞추어 37°C에서 30 분 반응시켰다. 반응 후 1 ml의 ethyl acetate를 넣고 1,000 rpm에서 10분 원심분리하고 새로운 마이크로 튜브로 상층액을 옮겨 speed vac을 사용하여 건조하였다. 이것을 50 ㎕의 초산에틸을 가하여 녹이고 박막크로마토그래피(Thin Layer Chromatography; TLC, Merck, Germany)판에 스폿한 후, TLC 챔버에 50% 에틸아세테이트와 50% 시클로헥산으로 구성된 전개용매를 넣어서 전개시켰다. 테스토스테론(T)은 UV 램프(UVGL-58, Upland, USA)를 사용하여 254 nm에서, 디하이드로테스토스테론(DHT)은 10% 황산을 뿌린 후 가열하여 확인하였다. T 및 DHT 부위는 오려내어 신틸레이션 바이알(Scintilation vial)에 넣고 5 ml의 칵테일을 넣었다. 리퀴드 신틸레이션 카운터(Liquid scintilation counter;LSC, Packard Instruments, 미국)를 사용하여 CPM (Counter Per Minute)을 측정하였고, 상기 실험에 따라 5α-환원효소 활성에 의한 테스토스테론(T)의 전환 율을 산출하고 대조군과 상대적인 5α-환원효소 저해율(%)에 대한 결과를 하기 표 2에 나타내었다.To a 1.5 ml microtube was added 250 μg of 5α-reductase, 120 nCi [1,2,6,7- 3 H] -T, 200 μM NADPH (Calbiochem, US) 6.6) and reacted at 37 ° C for 30 minutes. After the reaction, 1 ml of ethyl acetate was added, centrifuged at 1,000 rpm for 10 minutes, and the supernatant was transferred to a new microtube and dried using a speed vac. This was dissolved by adding 50 μl of ethyl acetate and spotted on a thin layer chromatography (TLC, Merck, Germany) plate. The TLC chamber was developed with a developing solvent composed of 50% ethyl acetate and 50% cyclohexane. Testosterone (T) was identified by heating at 254 nm using a UV lamp (UVGL-58, Upland, USA) and by dissolving 10% sulfuric acid in dihydrotestosterone (DHT). The T and DHT sections were cut and placed into a scintillation vial and 5 ml of cocktail was added. Counter Per Minute (CPM) was measured using a liquid scintilation counter (LSC, Packard Instruments, USA). The conversion rate of testosterone (T) by 5α-reductase activity was calculated according to the above- And the relative inhibition rate of 5? -Reductase (%) are shown in Table 2 below.
[표 2][Table 2]
실험 결과, 상기 표 2에서 보여지는 바와 같이 실시예의 조성물에 의하여 모든 처리농도에서 농도가 높을수록 저해율이 증가하여 5α-환원효소 활성이 최고 약 26 % 억제함을 보였다. 따라서, 한방 원료 조성물이 5α-환원효소 활성을 억제함으로써 모발 생장을 촉진하는 것으로 확인되었다.As shown in Table 2, the inhibitory activity of the 5α-reductase activity was inhibited up to about 26% by increasing the concentration at all treatments. Therefore, it was confirmed that the oriental raw material composition promotes hair growth by inhibiting 5? -Reductase activity.
하기에 본 발명의 추출물을 포함하는 조성물의 제형예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Formulation examples of the composition containing the extract of the present invention will be described below, but the present invention is not intended to be limited thereto but is specifically described.
제형예 1(헤어토닉의 제조)Formulation Example 1 (Production of hair tonic)
제형예 2(헤어컨디셔너의 제조)Formulation Example 2 (Preparation of hair conditioner)
제형예 3(헤어로션의 제조)Formulation Example 3 (Preparation of hair lotion)
(제형예 4 헤어비누의 제조)(Formulation Example 4: Production of hair soap)
이와 같이, 본 발명의 실시예에 따른 모발 개선용 조성물의 경우, 5α-환원효소 활성을 억제하여 래트 진모 모낭(Rat vibrissa hair follicle)의 분리 배양을 이용한 육모 성장 실험에서 뛰어난 효과를 나타내므로 탈모 예방, 개선 및 양모 효과를 제공할 수 있다.Thus, in the case of the hair improving composition according to the embodiment of the present invention, since the 5α-reductase activity is inhibited and the hair growth test using the isolated cultivation of the rat rhizome hair follicle (Rat vibrissa hair follicle) , Improvement and wool effect.
또한, 본 발명에 따른 모발 개선용 조성물은, 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어 에어로졸, 헤어 팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 또는 헤어스프레이의 제조에 사용될 수 있다.In addition, the hair improving composition according to the present invention can be used as a hair improving agent for a hair improving composition of the present invention, which can be used as a hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, hair treatment, Hair gel, hair gauze, hair dressing, cosmetic cream, hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair drying agent, hair preservative, hair dye, Hair lacquers, hair moisturizers, hair mousses or hair sprays.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090062850A KR101654308B1 (en) | 2009-07-10 | 2009-07-10 | Composition for improving hair having effect of depilation prevention and good hair |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090062850A KR101654308B1 (en) | 2009-07-10 | 2009-07-10 | Composition for improving hair having effect of depilation prevention and good hair |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110005363A KR20110005363A (en) | 2011-01-18 |
KR101654308B1 true KR101654308B1 (en) | 2016-09-07 |
Family
ID=43612535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090062850A Active KR101654308B1 (en) | 2009-07-10 | 2009-07-10 | Composition for improving hair having effect of depilation prevention and good hair |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101654308B1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101665319B1 (en) * | 2015-07-22 | 2016-10-12 | 주식회사 네이처센스 농업회사법인 | Functional composition for preventing and improving alopecia |
KR20180128439A (en) * | 2016-07-05 | 2018-12-03 | 윤호영 | Local Hair Removal Prevention and Hair Growing Agent Composition Room |
KR102354292B1 (en) * | 2019-07-02 | 2022-01-21 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating andropause syndrome comprising Vitex rotundifolia extract as effective component |
CN114903819A (en) * | 2021-02-10 | 2022-08-16 | 伽蓝(集团)股份有限公司 | Myrobalan fruit extract, preparation method and application thereof, and anti-alopecia product containing myrobalan fruit extract |
KR102586411B1 (en) | 2021-11-26 | 2023-10-12 | 아크로랩스 주식회사 | High-efficiency fuel processing device with durability that enables stable hydrogen production and carbon monoxide removal through heat exchange optimization |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100782273B1 (en) * | 2006-12-28 | 2007-12-04 | 안광주 | Hair Loss Prevention and Wool Promoting Composition |
-
2009
- 2009-07-10 KR KR1020090062850A patent/KR101654308B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100782273B1 (en) * | 2006-12-28 | 2007-12-04 | 안광주 | Hair Loss Prevention and Wool Promoting Composition |
Non-Patent Citations (1)
Title |
---|
"금주녹운유"에 관한 [한국전통지식포탈] DB 자료 출력물(2007.12.06.)* |
Also Published As
Publication number | Publication date |
---|---|
KR20110005363A (en) | 2011-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100839704B1 (en) | Hair growth and hair growth composition | |
KR101132246B1 (en) | The hair growth solution mainly comprised of ginsenoside rg3 and rh2, and the hair treatment composition | |
KR20120039384A (en) | The hair growth compositions containing flavonoids | |
PH12016500067B1 (en) | Composition for promoting hair sprouting and hair growth | |
KR101654308B1 (en) | Composition for improving hair having effect of depilation prevention and good hair | |
CN113633585B (en) | External hair care composition and preparation with effects of preventing alopecia, promoting hair growth and blackening hair and preparation method thereof | |
KR20160008055A (en) | Composition for improving hair or skin conditions comprising Camellia japonica leaf extract | |
WO2020127888A2 (en) | Urban darkening skin composition and formulation | |
KR102251495B1 (en) | Composition for treating hair loss and promoting hair growth | |
KR101252550B1 (en) | Cosmetic composition for protecting sebum secretion on the skin | |
KR20140131243A (en) | Composition for preventing hair loss or promoting hair growth comprising Ginsenoside F2 | |
KR20000022127A (en) | Scalp care compositions | |
KR20210131598A (en) | Composition for preventing hair loss or promoting hair growth, comprising Camellia japonica pericarp extract as an active ingredient | |
JPH1160450A (en) | Hair tonic | |
KR20120105922A (en) | External composition for promoting hair growth and preventing alopecia | |
KR101724870B1 (en) | Hair growth promoting composition having curative inflammation and Wnt /? - catenin signaling activity | |
JP2002284648A (en) | Hair restorer composition | |
KR20020008268A (en) | Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois | |
KR102174309B1 (en) | Cosmetic composition for prevention of losing hair or promotion of growing hair containing Taxillus yadoriki extract | |
KR101362236B1 (en) | Composition containing oriental herb for anti-alopecia | |
KR102495343B1 (en) | Cosmetic Composition for promoting hair growth or preventing hair loss with the extraco of Schisandra Chinensis Seed | |
KR101182743B1 (en) | Producing method of lacquer tree extraction removing urushiol using grifola frondosa and cosmetic compositon for preventing falling out of the hair | |
JP5866139B2 (en) | Pleurotus extract used in pharmaceutical and cosmetic compositions | |
TWI353249B (en) | Hair growth agent composition | |
US8617622B2 (en) | Extracts and compounds from Ficus benghalensis for increasing hair growth and decreasing hair loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20090710 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20140610 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20090710 Comment text: Patent Application |
|
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150831 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20160627 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150831 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20160627 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20160201 Comment text: Amendment to Specification, etc. |
|
PX0701 | Decision of registration after re-examination |
Patent event date: 20160829 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20160728 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20160627 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20160201 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20160830 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20160831 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20190716 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20190716 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20200722 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20210716 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20220706 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20230718 Start annual number: 8 End annual number: 8 |